Skip to content

Psilocybin: all studies

Page 68 of 440: studies 671 to 680 of 4,392, newest first. Back to the psilocybin overview

Research

Improving Best Practice Indicators for Psilocybin Assisted Therapy Using a Mul-tiphase Mixed Methods Delphi Study

International Journal of Multiple Research Approaches April 30, 2025 Kim Hoffman, Todd P. Korthuis, Kellie Pertl et al. 2 citations

Most Delphi studies primarily rely on questionnaires and subsequent quantitative ratings across multiple rounds to learn about a complex issue. This article demonstrates the integration of qualitative inquiry into a Delphi study to enhance and complement quantitative findings. We conducted a mixed methods Delphi study to establish a comprehensive list of quality and safety indicators for best...

Therapeutic Effects of Low-Dose Psilocybin in Depression and Other Mental Disorders: A Systematic Review

Psychedelic Medicine April 28, 2025 Shakila Meshkat, Howell Fang, Rachel Sousa-Ho et al.

Introduction: High-dose psilocybin has shown potential in treating various psychiatric disorders, but its perceptual and cognitive effects, along with the risk of adverse events, highlight the need for alternative treatment approaches. One such approach is the use of low-dose psilocybin, which does not significantly alter cognition or perception. While low-dose psilocybin has garnered growing...

Calcium Activation Mechanism of a Noncanonical Aromatic L-Amino Acid Decarboxylase from Psilocybin Mushroom

Research Square April 28, 2025 Yi Wang, Tianjie Li, Erin S. Reynolds et al. preprint

Abstract PcncAAAD is a calcium-activatable noncanonical aromatic L-amino acid decarboxylase (AAAD) featuring a unique appendage C-terminal domain (CTD) and two metal-binding sites. In this study, we establish an in silico RMSD-based evaluation model through molecular dynamics simulations, validated by in vitro enzyme assays, to decipher the enzyme’s calcium activation mechanism. Between the two...

University Students’ Motives for Psilocybin Use: A Mixed-Methods Analysis

Journal of Drug Issues April 26, 2025 Shayla Frinton, Jill O. Robinson

Motives are a highly influential force in substance use and vary depending on the substance or dose being used. Little research has compared motives across different doses of psilocybin. Psilocybin is often ingested in microdoses (0.1–0.4 g) or macrodoses (1 g+), each producing unique perceptual and mood effects. The current study examined whether motives for microdose and macrodose psilocybin...

Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises

Molecular Psychiatry April 26, 2025 Rebecca Harding, Neomi Singer, Talma Hendler et al. 4 citations

Abstract Psilocybin therapy (PT) is emerging as an effective intervention for Major Depressive Disorder (MDD), offering comparable efficacy to conventional treatments like selective serotonin reuptake inhibitors (SSRIs). Music, an emotionally evocative stimulus, provides a valuable tool to explore changes in hedonic and predictive processing mechanisms via expectancy violations, or ‘surprises’....

Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysis

The International Journal of Psychiatry in Medicine April 25, 2025 Damian Swieczkowski, Aleksander Kwaśny, Michal Pruc et al. 4 citations

Objective To evaluate psilocybin's efficacy in reducing depressive and anxiety symptoms in cancer patients based on randomized controlled trials (RCTs). Methods This systematic review and network meta-analysis (NMA) followed PRISMA and Cochrane Handbook guidelines. PubMed, Embase and Cochrane Library data up to July 2024 were analyzed. Two RCTs met the inclusion criteria. Changes in Beck...

DOI: 10.1177/00912174251337572 (opens in new tab) Major depressive disorder Palliative medicine Palliative psychiatry Rapid-acting antidepressants +5

The phenomenology of psilocybin: transformative insights for research and clinical practice

Frontiers in Psychology April 25, 2025 Antonio Metastasio, Elisabeth Prevete, Sofia Venturini et al. 8 citations

Introduction Considering the increasing evidence supporting psilocybin’s efficacy in therapeutic settings, it is essential to deepen our understanding of its subjective meanings and effects to enhance its integration into psychotherapy. Current knowledge is primarily based on psychometric assessments or unstructured personal reports, leaving a gap in the qualitative analysis of subjective...

Editorial: Beyond psilocybin: exploring the clinical potential of alternative and novel psychedelics.

Frontiers in Psychiatry April 23, 2025 Martin L Williams, Deborah Rudin, Yasmin Schmid et al.

However, psilocybin is but one of scores of compounds belonging to two main chemical classesphenethylamines and tryptamines -along with ergolines and an expanding array of other (mostly heterocyclic) alkaloids -that act as agonists of the serotonin 5-HT2A, 5-HT2C and 5-HT1A receptors responsible for the various phenomenological and putative therapeutic effects of classic psychedelics (8). In...

DOI: 10.3389/fpsyt.2025.1600812 (opens in new tab) Full text (opens in new tab) Psychedelic medicine Mental health treatments Alternative therapy Drug research +1

Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs

Psychopharmacology April 23, 2025 Nicholas C. Borgogna, Tyler Owen, Dan Petrovitch et al. 8 citations

Abstract Rationale Psilocybin is a potentially paradigm-shifting depression intervention. We conducted a systematic review and meta-analysis of psilocybin-for-depression randomized controlled trials (RCTs). Objectives Systematically assess harm reporting, risk of bias, action mechanism specification, and incremental therapeutic effect sizes in the psilocybin-for-depression RCT literature....

Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol

Wellcome Open Research April 22, 2025 Matthew Butler, Catherine Bird, Carolina Maggio et al. 3 citations

Background Functional neurological disorder (FND) is a common cause of neurological symptoms including seizures and movement disorders. It can be debilitating, is associated with high health and social care costs, and can have a poor prognosis. Functional magnetic resonance imaging (fMRI) has suggested FND is a multi-network disorder. Converging evidence suggests that other mechanisms including...

DOI: 10.12688/wellcomeopenres.22543.2 (opens in new tab) Psilocybin Magnetic resonance imaging Functional imaging Functional connectivity +2